New bronchodilators and combinations in COPD treatment

Günay, Si̇bel; Sarıaydın, Muzaffer; Demirci, Nilgün Yılmaz

doi:10.5578/tt.10267

Cited by 6 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a singledose inhaler treatment per day in the management of stable COPD became a topical concern in recent years after the development of new extremely long-lasting bronchodilator medication. 8 With the development of long-acting anticholinergics, long-actingβ-agonists, and ICS, there have been significant adjustments in the comprehensive understanding and management of the disease. The use of ICS is recommended by the current GOLD guidelines for patients with severe and very severe airflow limitations, as well as for patients who experience frequent exacerbations.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of chronic obstructive pulmonary disease

Shalabi,

Aqdi,

Alfort

et al. 2023

Int J Community Med Public Health

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a lung condition marked by restricted lung airflow. It is a globally prevalent condition affecting almost 300 million individuals. COPD is linked to a significant burden of morbidity and mortality thus necessitating early diagnosis and management. Rising COPD treatment options complicate care and necessitate a review of clinical data to guide treatment choices. Corticosteroids and bronchodilators are the mainstay of treatment for COPD due to their safety and efficacy. Compared to inhaled corticosteroids or long-acting β-agonist therapy alone, inhaled corticosteroids plus long-acting β-agonist lower the risk of exacerbations and enhance lung function and health status in patients with COPD. Patients who experience frequent exacerbations despite taking long-acting bronchodilators and those who have evidence of eosinophilic bronchial inflammation, as shown by high blood eosinophil levels and/or a history of asthma or asthma-COPD overlap, may both benefit greatly from inhaled corticosteroids therapy. Although not widespread, inhaled corticosteroid use is linked to an elevated risk of pneumonia and may vary depending on the particular corticosteroid utilized. Recent research on combination therapy of inhaled corticosteroids and long-acting β-agonist has shown significant advantages and supports its widespread use in COPD patients who experience frequent exacerbations however some clinical studies and trials have also demonstrated quite conflicting outcomes to this therefore necessitating the need for further clinical trials to exhibit conclusive results. The purpose of this research is to review the available information about the effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of chronic obstructive pulmonary disease

Shalabi,

Aqdi,

Alfort

et al. 2023

Int J Community Med Public Health

View full text Add to dashboard Cite

show abstract

“…Bronchodilator therapy in COPD did not change significantly. After the emergence of new ultra-long-lasting bronchodilator medicines in recent years, a single-dose inhaler treatment per day in the management of stable COPD has become a topical concern ( 4 ). COPD treatment now includes combinations of two long-acting adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs).…”

mentioning

confidence: 99%

Simultaneous UPLC Assay for Oxitropium Bromide and Formoterol Fumarate Dihydrate in Pressurized Metered Dose Inhaler Products for Chronic Obstructive Pulmonary Disease

Seckin,

Saglik Aslan

2023

Journal of AOAC International

View full text Add to dashboard Cite

Backround Oxitropium Bromide (OB) and Formoterol Fumarate Dihydrate (FFD) are inhaler molecules that are widely used in the treatment of chronic lung diseases. Objective The goal of this work was to create a reversed phase-ultra performance liquid chromatography (RP-UPLC) technique for assay and identification of OB and FFD, as well as identification and estimate of its associated compounds in pressurised metered dose inhaler product (pMDI). Method Separation of oxitropium and formoterol peaks were enhanced on C18 (50 x 2.1 mm x 1.7 μm), UPLC column with Ethylene-Bridged-Hybrid technology, The mobile phase consists of buffer (0.07 M KH2PO4) and acetonitrile (80:20 v/v). The detector wavelength of 210 nm, flow rate of pump 0.6 mL/min and oven temperature for column were set at 25◦C. The injection volume was 10 μL. The method run time is 2 min. The mobile phase was used as the solvent. Results Retention times were 0.5 min. for OB and 1.0 min. for FFD. The assay analysis was lineear range for all analytes within the range for concentrations 0.03—14.8 µg/mL of OB, 0.01– 0.88 µg/mL of FFD. LOD values and LOQ values 0.009 µg/mL and 0.026 µg/mL for OB, 0.003 µg/mL and 0.009 µg/mL for FFD, respectively. Recoveries were obtained at 96.3% for OB and 97.2% for FFD. Precisions values were (as RSD%) ≤1.5%. Conclusions With the UPLC method developed and validated according to the current ICH guidelines, it is possible to simultaneously detect OB and FFD of assay analysis in pMDI products accurately, precisely and selectively, independent of the matrix effect. Highlights The present method is the first method in the literature based on the UPLC method for this purpose. The UPLC method is a time-saving method, it provides a faster and cheaper technique than the HPLC method.

show abstract

“…Расширение бронхов достигается, в первую очередь, посредством локального повышения активности симпатической нервной системы в бронхах, то есть активацией β 2 -адренорецепторов, либо подавлением парасимпатических влияний на фоне блокады М-холинергических рецепторов. На протяжении последних двадцати лет общая концепция механизмов реализации бронхолитического действия не менялась (Günay et al, 2016). Между тем, в качестве адъювантной фармакологической активности рассматривается потенциальное противовоспалительное действие, обусловленное стабилизацией тучных клеток и подавлением их дегрануляции с выбросом провоспалительных и бронхоконстрикторных медиаторов.…”

unclassified

Levosalbutamol as alternative to drugs on the basis of racemic salbutamol: Review of the results of pre-clinical research

Miroshnichenko

Bulgakova

Perfiliev

et al. 2017

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

The aim of the work is to conduct an analytical review of the results of preclinical studies of levosalbutamol. The review discusses the pharmacodynamic features of the R-stereoisomer of salbutamol in vitro. The chemical bases of interaction of levosalbutamol with β 2 -adrenoreceptors, intracellular signaling cascades associated with β 2 -adrenoreceptors, and structural features of clinically significant ligands of β 2 -adrenoreceptors are presented. Broncholytic activity, influence on the contractility of the diaphragmatic muscles, mucociliary clearance of R-salbutamol in comparison with racemic salbutamol are described. The data presented indicate that all known β 2 -adrenergic receptor-dependent effects of racemic salbutamol, including bronchodilation, are realized by its R-enantiomer. There is evidence that the regular inhalation administration of racemic salbutamol is accompanied by a partial decrease in the bronchoprotective effect and an increase in airway hyperreactivity in response to the action of provocative factors. It was found that the development of hyperreactivity of the respiratory tract is excluded in the case of regular inhalation of levosalbutamol. Possible mechanisms of the paradoxical bronchoconstrictor effect of the salbutamol dystomer are described. This article shows the beneficial effect of levosalbutamol on mucociliary clearance, its anti-inflammatory activity and antiallergic effect. The image data are compared between the enantiomers and the racemate of salbutamol. Special attention is paid to the pharmacokinetics of enantiomers of salbutamol. The data presented from the preclinical studies provide evidence of chiral inversion of stereoisomers of salbutamol.Левосальбутамол как альтернатива лекарственным препаратам на основе рацемического сальбутамола: обзор результатов доклинических исследований А. Г. Мирошниченко, Я. С. Булгакова, В. Ю. Перфильев, Н. Г. Базарнова Алтайский государственный университет, Барнаул, РоссияПроанализированы результаты доклинических исследований лекарственного средства левосальбутамол. Обсуждаются фармакодинамические особенности R-стереоизомера сальбутамола in vitro. Представлены химические основы взаимодействия левосальбутамола с β 2 -адренорецепторами, внутриклеточные сигнальные каскады, ассоциированные с β 2 -адренорецепторами, а также структурные особенности клинически значимых лигандов β 2 -адренорецепторов. Описана бронхолитическая активность, влияние на контрактильность диафрагмальных мышц, мукоцилиарный клиренс R-сальбутамола по сравнению с рацемическим сальбутамолом. Приведены данные, которые указывают на то, что все известные β 2 -адренорецепторзависимые эффекты рацемического сальбутамола, включая бронходилатацию, реализуются за счет его R-энантиомера. Имеются свидетельства того, что регулярное ингаляционное введение рацемического сальбутамола сопровождается парциальным снижением бронхопротективного эффекта и увеличением гиперреактивности дыхательных путей в ответ на действие провокационных факторов. При этом развитие гиперреактивности дыхательных п...

show abstract

New bronchodilators and combinations in COPD treatment

Cited by 6 publications

References 18 publications

Effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of chronic obstructive pulmonary disease

Effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of chronic obstructive pulmonary disease

Simultaneous UPLC Assay for Oxitropium Bromide and Formoterol Fumarate Dihydrate in Pressurized Metered Dose Inhaler Products for Chronic Obstructive Pulmonary Disease

Levosalbutamol as alternative to drugs on the basis of racemic salbutamol: Review of the results of pre-clinical research

Contact Info

Product

Resources

About